Clinical Trials Logo

Pemphigoid, Bullous clinical trials

View clinical trials related to Pemphigoid, Bullous.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05061771 Withdrawn - Bullous Pemphigoid Clinical Trials

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

ARREST-BP
Start date: May 6, 2022
Phase: Phase 3
Study type: Interventional

A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5) and the lipid mediator LTB4 may have a central role in driving the disease. In this study patients will be randomized to receive either nomacopan plus oral corticosteroids (OCS) or placebo plus OCS for a treatment period of 24 weeks. OCS will be tapered over the course of the treatment if the symptoms of disease improve.

NCT ID: NCT03421548 Withdrawn - Glaucoma Clinical Trials

Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1

BKPro
Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and performance of the EYEMATE system in patients undergoing concomitant implantation of a BKPro type 1 and an EYEMATE sensor over the 24 months period beginning at implantation.

NCT ID: NCT02126020 Withdrawn - Clinical trials for Stevens-Johnson Syndrome

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro and loss of the eye. Infliximab is an antibody against tumor necrosis factor alpha and is used intravenously to control inflammation in several diseases. It has been used in some cases of corneal melting with significant success. This study's hypothesis is that infliximab can be successfully used as an eye drop (instead of the usual administration through veins) and that its regular use may prevent melt in eyes with a Boston Keratoprosthesis type I and underlying auto-immune disease.